TRT on TikTok: separating real benefits from bro-science

What's this video probably claiming?

Accounts like @moreroidsmorefoidz occupy a specific corner of TikTok where TRT gets framed as the answer to every male complaint: low energy, poor gym performance, brain fog, low libido, and general life dissatisfaction. Based on the hashtag set and creator handle, this video is almost certainly pushing one or more of the following: that TRT produces dramatic body composition changes, that most men are unknowingly hypogonadal, that doctors are gatekeeping testosterone unnecessarily, or that optimizing levels above the clinical normal range produces better outcomes. These are the four horsemen of TRT content on short-form video. Some of these ideas have a grain of truth buried under significant exaggeration. The handle itself is worth noting. Framing TRT as "more roids" signals a performance-enhancement orientation rather than a clinical hypogonadism framing, which has real implications for how the audience interprets dosing and risk information.

What does the science actually show?

TRT has a legitimate, well-studied role in treating classical hypogonadism, defined clinically as total testosterone consistently below 300 ng/dL with corresponding symptoms, confirmed on at least two morning samples. A 2018 meta-analysis by Bhasin et al. in the New England Journal of Medicine found that TRT in genuinely hypogonadal men improved sexual function, bone density, and lean mass. The Testosterone Trials, a coordinated set of seven placebo-controlled studies published across multiple journals between 2016 and 2018, showed modest but real improvements in sexual desire, walking distance, and bone density in men 65 and older with low testosterone. However, those same trials showed no significant cognitive benefit and raised cardiovascular signals that remain unresolved. A 2023 JAMA Cardiology paper by Lincoff et al. on the TRAVERSE trial reported non-inferiority for major cardiovascular events at standard doses, but elevated rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the treatment group compared to placebo.

Where does the social media noise diverge from clinical reality?

The biggest divergence is on thresholds. TikTok TRT culture has effectively moved the goalpost from "below 300 ng/dL with symptoms" to "below 700 ng/dL is suboptimal." There is no published randomized controlled evidence supporting the idea that raising testosterone from 450 to 900 ng/dL in a symptomatic man without classical hypogonadism produces meaningful clinical benefit. The second divergence is on side effects. Erythrocytosis, the elevation of red blood cell mass, occurs in roughly 20 to 30 percent of men on injectable testosterone according to a 2021 review by Bachman et al. in the Journal of Clinical Endocrinology and Metabolism. This raises thrombosis risk and requires monitoring, but short-form video almost never mentions it. Testicular atrophy and suppression of the hypothalamic-pituitary-gonadal axis are also routinely omitted. Fertility impacts are significant and often permanent without concurrent use of agents like hCG, which itself carries regulatory and clinical complexity.

What should you actually know?

If you are watching TRT content on TikTok and considering therapy, here is what the clinical literature actually supports. Diagnosis requires two fasting morning testosterone draws, ideally with LH, FSH, and SHBG panels to distinguish primary from secondary hypogonadism. Symptoms alone are not sufficient. The Endocrine Society guidelines published by Bhasin et al. in 2018 explicitly recommend against prescribing TRT to men with age-related decline in testosterone who do not meet the biochemical threshold. Delivery method matters. Injectable testosterone cypionate or enanthate produces larger peak-to-trough swings than gels or patches, which affects both symptom stability and hematocrit elevation. Pellets have highly variable absorption. Monitoring is not optional. Hematocrit, PSA, and testosterone levels should be checked at 3 and 6 months after initiation and annually thereafter. Anyone telling you TRT is a simple, low-risk lifestyle upgrade is not reading the same studies that clinicians are reading.